This population-based study evaluated whether sentinel lymph node biopsy (SLNB) status improves adjuvant therapy decision-making in stage IIB/C melanoma. SLNB results provided meaningful prognostic stratification that influenced adjuvant treatment recommendations, supporting its routine use in this patient population.

SLNB provides valuable prognostic information that directly impacts adjuvant therapy decisions in stage IIB/C melanoma.

Routine SLNB should be strongly considered in stage IIB/C melanoma to guide personalized adjuvant treatment planning.